| Literature DB >> 31137657 |
Ines Barkia1, Nazamid Saari2, Schonna R Manning3.
Abstract
Microalgae represent a potential source of renewable nutrition and there is growing interest in algae-based dietary supplements in the form of whole biomass, e.g., Chlorella and Arthrospira, or purified extracts containing omega-3 fatty acids and carotenoids. The commercial production of bioactive compounds from microalgae is currently challenged by the biorefinery process. This review focuses on the biochemical composition of microalgae, the complexities of mass cultivation, as well as potential therapeutic applications. The advantages of open and closed growth systems are discussed, including common problems encountered with large-scale growth systems. Several methods are used for the purification and isolation of bioactive compounds, and many products from microalgae have shown potential as antioxidants and treatments for hypertension, among other health conditions. However, there are many unknown algal metabolites and potential impurities that could cause harm, so more research is needed to characterize strains of interest, improve overall operation, and generate safe, functional products.Entities:
Keywords: Microalgae; anti-inflammatory activity; antihypertensive activity; antioxidant activity; bioactive compounds; health benefits
Mesh:
Substances:
Year: 2019 PMID: 31137657 PMCID: PMC6562505 DOI: 10.3390/md17050304
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Bioactive compounds from microalgae include: carotenoids, β-carotene (a). astaxanthin (b), and fucoxanthin (c); phycobilins, phycocyanin (d) and phycoerythrin (e); sulfated polysaccharides (f); omega-3 fatty acids, docosahexaenoic acid (g), docosapentaenoic acid (h), and eicosapentaenoic acid (i); and phenolics, rutin (j) and eckol (k).
Major microalgal products and producers for human nutrition (adapted from [12,28]).
| Microalgae (form) | Major Producer | Origin | Annual Production | World Production (tons/year) |
|---|---|---|---|---|
| Earthrise Nutraceuticals | USA | 450 | 4100–6700 | |
| Cyanotech Corporation | USA | 360 | ||
| Hainan DIC Microalgae | China | 350 | ||
| Japan Algae Co., Ltd. | Japan | 30–100 | ||
| Parry Nutraceuticals | India | >175 | ||
| FEMICO | Taiwan | 50–150 | ||
| Nan Pao International Biotechnology Co. Ltd. | Taiwan | 70 | ||
| Biorigin | Switzerland | 60 | ||
| TAAU Australia Pty Ltd. | Australia | 50–60 | ||
| Taipei | Taiwan | 400 | 2000 | |
| Roquette Klötze | Germany | 130–150 | ||
| Blue Biotech | Germany | * | ||
| Earthrise Nutritionals | USA | * | ||
| β-carotene from | Cognis Nutrition & Health Co. | Australia | * | 1200 |
| Nature Beta Technology Ltd. | Israel | * | ||
| Astaxanthin from | Cyanotech Corp. | USA | * | 300 |
| Mera Pharmaceuticals Inc. | USA | * | ||
| Fuji Chemical Industries | Japan | * | ||
| BioReal AB | Sweden | * |
* data not available.
Biochemical composition of different species of microalgae.
| Species | Class | % Protein ( | % Carbs ( | % Fat ( | References |
|---|---|---|---|---|---|
|
| Bacillariophyceae | 34.8 | 16.8 | 16.1 | [ |
|
| Bacillariophyceae | 26 | 9.8 | 13 | [ |
|
| Chlorophyceae | 48 | 17 | 21 | [ |
|
| Chlorophyceae | 11 | - | - | [ |
|
| Chlorophyceae | 12 | - | - | [ |
|
| Chlorophyceae | 57 | 32 | 6 | [ |
| Chlorophyceae | 34.17 | 14.57 | 14.36 | [ | |
|
| Chlorophyceae | 48–56 | 10–17 | 12–14 | [ |
| Chlorophyceae | 31 | 28 | 15 | [ | |
|
| Coscinodiscophyceae | 34 | 6.0 | 16 | [ |
|
| Coscinodiscophyceae | 40 | 37 | 23 | [ |
|
| Coscinodiscophyceae | 12 | 4.7 | 7.2 | [ |
|
| Coscinodiscophyceae | 59 | 10 | 31 | [ |
|
| Coscinodiscophyceae | 25 | 4.6 | 10 | [ |
|
| Coscinodiscophyceae | 34 | 8.8 | 19 | [ |
|
| Cyanophyceae | 60–71 | 13–16 | 6-7 | [ |
| Cyanophyceae | 63 | 15 | 11 | [ | |
| Eustigmatophyceae | 30 | 10 | 22 | [ | |
|
| Eustigmatophyceae | 18–34 | 27–36 | 24–28 | [ |
| Pavlovophyceae | 24–29 | 6–9 | 9–14 | [ | |
|
| Porphyridiophyceae | 28–39 | 40-57 | 9–14 | [ |
|
| Prasinophyceae | 31–46 | 25 | 12 | [ |
| Prasinophyceae | 36 | 24 | - | [ | |
| Prymnesiophyceae | 28–45 | 25–33 | 22–38 | [ | |
|
| Prymnesiophyceae | 27 | 34 | 11 | [ |
| Thraustochytriaceae | - | - | 50–77 | [ | |
|
| Trebouxiophyceae | 39–40 | 19–31 | 25–34 | [ |
|
| Trebouxiophyceae | 57 | 26 | 2 | [ |
|
| Trebouxiophyceae | 51–58 | 12–17 | 14–22 | [ |
Market value of selected high-value products isolated from microalgae compared to whole biomass.
| Product | Price (USD kg−1) | References |
|---|---|---|
| Astaxanthin | 2500–7000 | [ |
| β-carotene | 300–1500 | [ |
| Omega-3 fatty acids | 80–160 | [ |
| 44 | [ | |
| 42 * | [ |
* Value expressed in € by the authors; the value shown was converted to USD ($1.17 USD/€).
Bioactive compounds from microalgae and their potential health benefits.
| Bioactive Compounds | Source | Health Benefits | References |
|---|---|---|---|
|
| |||
|
|
| Antioxidant, pro-vitamin A, anti-allergic, anti-inflammatory | [ |
|
|
| Antioxidant, anti-inflammatory | [ |
|
|
| Antioxidant, anti-inflammatory | [ |
|
| |||
|
| Improves normal growth, visual and functional development in infants | [ | |
|
| Cardiovascular benefits, mental development and support, anti-inflammatory, protection against atherosclerosis | [ | |
|
| Cardiovascular benefits, improves nervous system development and function of the brain | [ | |
|
| |||
|
|
| Antioxidant, anti-inflammatory, anticancer, antihypertensive | [ |
|
| Antioxidant | [ | |
|
|
| Antioxidant, anti-inflammatory | [ |
|
| antioxidant, anti-inflammatory, antiviral, immunomodulatory | [ | |
|
| Anti-inflammatory, analgesic, antioxidant, antiproliferative | [ | |